Sphera Funds Management LTD. grew its position in Translate Bio Inc (NASDAQ:TBIO) by 112.8% during the 3rd quarter, Holdings Channel reports. The firm owned 276,639 shares of the company’s stock after acquiring an additional 146,639 shares during the quarter. Sphera Funds Management LTD.’s holdings in Translate Bio were worth $2,766,000 as of its most recent SEC filing.
A number of other hedge funds have also recently modified their holdings of TBIO. FMR LLC acquired a new position in Translate Bio in the 2nd quarter worth about $73,437,000. Bain Capital Public Equity Management LLC acquired a new position in Translate Bio in the 2nd quarter worth about $12,332,000. Federated Investors Inc. PA acquired a new position in Translate Bio in the 2nd quarter worth about $8,984,000. BlackRock Inc. increased its position in Translate Bio by 184.4% in the 3rd quarter. BlackRock Inc. now owns 426,770 shares of the company’s stock worth $4,268,000 after purchasing an additional 276,715 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in Translate Bio by 148.5% in the 3rd quarter. Wells Fargo & Company MN now owns 273,313 shares of the company’s stock worth $2,733,000 after purchasing an additional 163,313 shares during the last quarter. 49.48% of the stock is currently owned by institutional investors.
Shares of NASDAQ TBIO opened at $8.53 on Friday. The company has a quick ratio of 16.71, a current ratio of 16.72 and a debt-to-equity ratio of 0.91. Translate Bio Inc has a 52 week low of $5.00 and a 52 week high of $16.60.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.chaffeybreeze.com/2018/12/08/sphera-funds-management-ltd-raises-holdings-in-translate-bio-inc-tbio.html.
About Translate Bio
Translate Bio, Inc, a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency.
Featured Article: Investing in Growth Stocks
Want to see what other hedge funds are holding TBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Translate Bio Inc (NASDAQ:TBIO).
Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.